Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Prolight Diagnostics

18.28 SEK

+0.55 %

Less than 1K followers

PRLD

Nordic SME

Medical Equipment & Services

Health Care

+0.55 %
0.00 %
+2.12 %
+2.12 %
-20.52 %
-57.78 %
-35.37 %
-87.67 %
-53.56 %

Prolight Diagnostics develops point-of-care (POC) systems. These are small mobile instruments with disposable test cards that can perform In-Vitro Diagnostic (IVD) tests from a drop of blood. The POC system can contribute to faster and more accurate diagnoses of acute conditions. The company's launch product will be a highly sensitive measurement of troponin to be able to determine and exclude heart attacks.

Read more
Market cap
220.18M SEK
Turnover
45.8K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.5.
2026

Interim report Q1'26

26.5.
2026

General meeting '26

27.8.
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
And then for a slightly more up-to-date situational analysis: the company has turned out to be a disappointment in my case. Schedules are slipping and there is still no information about the clinical trial. I would estimate that new share issues will be arranged by May at the latest...
1/29/2026, 1:44 PM
2
Did anyone attend the shareholders’ meeting or the investor presentation held at the end of the month? I would be very interested to know what the management said about future schedule targets. I find the company’s communication regarding the schedules rather odd. Pre-validation ...
7/3/2025, 7:26 AM
2
Tänään tuli ensimmäiset tulokset (25/120) tuoreen veren tutkimuksista. Kurssi pomppasi aluksi tarjoten hyvän myyntipaikan. Kaikkiin tutkimusuutisiin liittyviin pomppuihin kannattaa myydä niin paljon kuin likviditeettiä riittää, koska tuloksien odotetaan olevan hyviä, jolloin tutkimuksen...
6/16/2025, 2:34 PM
by Gubrick
2
NOTE: This post has been sitting in draft mode since August, and I only noticed it now. Some time has passed, so the information might be outdated. Psyros is about to receive a new Europe-wide patent. I see this patent as quite significant; in general, the European Patent Office ...
1/29/2026, 1:34 PM
1
It probably wouldn’t make it to the main list, no. Here is the schedule included in the investor presentation held at the end of last month on 24.6: Pre-clinical validation studies are marked for H1 2025. Although it seems that St Thomas’ studies will continue for a while longer....
7/3/2025, 11:07 PM
1
Excellent result. H1 2026 is at least entirely time to try and seek a deal. It wouldn’t even need to cover the entire funding need, because after that, money could be brought in again with good valuation and small dilution.
7/2/2025, 7:28 AM
by Gubrick
1
Yesterday, an article was published with the headline “Prolight finalises instrument design and prepare for pilot manufacturing”. However, the article rather describes that the instrument is still being finalized, consistent with previous press releases. placera.se Prolight slutf...
1/30/2026, 12:13 PM
0
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.